TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$99 Million

Aura Biosciences, Inc.

Follow-on Offering

Bookrunner, November 2023

Aura Biosciences, Inc.

Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”) is a clinical-stage biotechnology company developing Virus-like Drug Conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. The Company’s initial focus is on ocular and urologic oncology where the disease is diagnosed early and there is a high unmet medical need for targeted local therapies. Aura’s proprietary platform enables the targeting of a broad range of solid tumors using Virus-like Particles (VLPs), that can be conjugated with drugs or loaded with nucleic acids to create VDCs. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved where the standard of care leaves many patients with blindness.